Rafa Laboratories
Rafa Laboratories Ltd., a pharmaceutical company, manufactures, markets, and distributes prescription (Rx) and over-the-counter (OTC) medicines in Israel. Based in Jerusalem.
Rafa Laboratories: net income sharply up (+151.6%), sales sharply up (+28.8%), operating income sharply up (+156.9%).
- Net income sharply upH1 2026
Net income: ₪33M, vs. ₪13M a year earlier, i.e. +151.6%.
- Sales sharply upH1 2026
Revenue: ₪190M, vs. ₪148M a year earlier, i.e. +28.8%.
- Operating income sharply upH1 2026
Operating income: ₪38M, vs. ₪15M a year earlier, i.e. +156.9%.
- Cash flow sharply upH1 2026
Operating cash flow: ₪45M, vs. ₪15M a year earlier, i.e. +197.4%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + H1 2026 − same period a year earlier). Sector median: companies in the group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 312 | 287 | 335 |
| Current assets | 174 | 154 | 197 |
| Non-current assets | 138 | 133 | 137 |
| Equity | 251 | 192 | 231 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 49 | 82 | 90 |
| Non-current liabilities | 12 | 12 | 14 |
| Revenue | 190 | 148 | 418 |
| Gross profit | 81 | 57 | 198 |
| Operating income | 38 | 15 | 112 |
| Pre-tax income | 37 | 15 | 111 |
| Net income | 33 | 13 | 100 |
| Net income (attributable to shareholders) | 33 | 13 | 100 |
| Dividends paid | −15 | −55 | −105 |
| Operating cash flow | 45 | 15 | 99 |
In millions of shekels. The "H1" columns cover the first six months of the year.
Calculated from these figures
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 42.6% | 38.5% | 47.3% |
| Operating margin | 19.8% | 9.9% | 26.7% |
| Net margin | 17.5% | 8.9% | 24.0% |
| Current ratio (current assets / current liabilities) | 3,6 x | 1,9 x | 2,2 x |
| Equity / total assets | 80.5% | 67.0% | 69.0% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Rafa Laboratories Ltd., a pharmaceutical company, manufactures, markets, and distributes prescription (Rx) and over-the-counter (OTC) medicines in Israel. The company offers sterile and aseptic injectable products, as well as formulations for combination devices such as auto-injectors. It also offers primary and secondary packaging solutions, including blisters, bottles, tubes, ampoules, cartridges, suppositories, and serialization services. In addition, it develops and offers auto-injector products for emergency use and protection against chemical warfare, as well as products to treat trauma, pain, and additional ABC (atomic, biological, and chemical) threats. The company was founded in 1937 and is based in Jerusalem, Israel.
Source: official company profile (Yahoo Finance), summary. Website: www.rafa.co.il
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).